Plato Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Plato Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$671K	Buy	4,006 +25	+0.6%	+$3.71K	0.04%	327
2026 Q1	$525K	Hold	3,981	–	–	0.04%	343
2025 Q4	$567K	Buy	3,981 +1,672	+72%	+$242K	0.04%	335
2025 Q3	$322K	Buy	2,309 +27	+1%	+$3.66K	0.02%	370
2025 Q2	$286K	Hold	2,282	–	–	0.02%	387
2025 Q1	$255K	Sell	2,282 -8,562	-79%	-$1.08M	0.02%	381
2024 Q4	$1.49M	Sell	10,844 -129	-1%	-$16K	0.11%	192
2024 Q3	$1.26M	Buy	10,973 +10,548	+2,482%	+$1.45M	0.1%	209
2024 Q2	$58.5K	Buy	425 +130	+44%	+$17.8K	0.01%	393
2024 Q1	$40.7K	Buy	+295	New	+$40.3K	﹤0.01%	387

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Plato Investment Management's NBIX Position: Q2 2026 in Review

Plato Investment Management increased its Neurocrine Biosciences (NBIX) stake by 0.63% in Q2 2026, buying an estimated $3.71K and bringing the position to 4,006 shares worth $671K. The position accounts for 0.04% of the portfolio, ranked #327.

Plato Investment Management first reported a position in NBIX in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.49M in Q4 2024. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Plato Investment Management held 4,006 shares of Neurocrine Biosciences worth $671K as of Q2 2026.
Plato Investment Management bought 25 Neurocrine Biosciences shares in Q2 2026, an estimated $3.71K.
Neurocrine Biosciences made up 0.04% of Plato Investment Management's portfolio in Q2 2026, its #327 holding.
Plato Investment Management first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 10 quarters since.
Plato Investment Management's Neurocrine Biosciences position peaked at $1.49M in Q4 2024.
781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Plato Investment Management's 13F filing for Q2 2026, filed 7 Aug 2026.